About: Development and validation of different indirect ELISAs for MERS-CoV serological testing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development and validation of different indirect ELISAs for MERS-CoV serological testing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development and validation of different indirect ELISAs for MERS-CoV serological testing
Creator	Azhar, Esam Alagaili, Abdulaziz Amor, Nabil Hashem, Anwar Hassan, Ahmed Mohammed, Osama Al-Amri, Sawsan Alhabbab, Rowa Siddiq, Loai Hindawi, Salwa Al-Subhi, Tagreed Alawi, Maha Mirza, Ahmed
Source	Elsevier; Medline; PMC
abstract	Abstract Since 2012, MERS-CoV has caused up to 2220 cases and 790 deaths in 27 countries with Saudi Arabia being the most affected country with ~83.1% of the cases and ~38.8% local death rate. Current serological assays such as microneutralization (MN), plaque reduction neutralization, immunofluorescence, protein microarray or pseudoparticle neutralization assays rely on handling of live MERS-CoV in high containment laboratories or need for expensive and special equipment and reagents and highly trained personnel which represent a technical hurdle for most laboratories in resource-limited MERS-CoV endemic countries. Here, we developed, compared and evaluated three different indirect ELISAs based on MERS-CoV nucleocapsid protein (N), spike (S) ectodomain (amino acids 1–1297) and S1 subunit (amino acids 1–725) and compared them with MN assay. The developed ELISAs were evaluated using large number of confirmed seropositive (79 samples) and seronegative (274 samples) MERS-CoV human serum samples. Both rS1- and rS-ELISAs maintained high sensitivity and specificity (≥90%) across a wider range of OD values compared to rN-ELISA. Moreover, rS1- and rS-based ELISAs showed better agreement and correlation with MN assay in contrast to rN-ELISA. Collectively, our data demonstrate that rS1-ELISA and rS-ELISA are more reliable than rN-ELISA and represent a suitable choice for seroepidemiological testing and surveillance in MERS-CoV endemic regions.
has issue date	2019-03-31(xsd:dateTime)
bibo:doi	10.1016/j.jim.2019.01.005
bibo:pmid	30659836
has license	els-covid
sha1sum (hex)	da59c7ef76390e0e97e6e57f5ff689152b14f6a2
schema:url	https://doi.org/10.1016/j.jim.2019.01.005
resource representing a document's title	Development and validation of different indirect ELISAs for MERS-CoV serological testing
has PubMed Central identifier	PMC7094657
has PubMed identifier	30659836
schema:publication	Journal of Immunological Methods
resource representing a document's body	covid:da59c7ef76390e0e97e6e57f5ff689152b14f6a2#body_text
is schema:about of	named entity 'UP TO' named entity 'LIMITED' named entity 'REGIONS' named entity '1297' named entity 'HTTPS' named entity 'HUMAN SERUM' named entity 'ENDEMIC' named entity 'IMMUNOFLUORESCENCE' named entity 'SPIKE' named entity 'ECTODOMAIN' named entity 'SAUDI ARABIA' named entity 'SERONEGATIVE' named entity 'CONTAINMENT' named entity 'HAVE' named entity 'AFFECTED' named entity 'RANGE' named entity 'CORRELATION' named entity 'HIGH' named entity 'RS1' named entity 'DEATH RATE' named entity 'SAMPLES' named entity 'serum' named entity 'testing' named entity 'samples' named entity 'surveillance' named entity 'amino acids' named entity 'COUNTRY' named entity 'LABORATORIES' named entity 'AGREEMENT' named entity 'TECHNICAL' named entity 'PERSONNEL' named entity 'SUBUNIT' named entity 'MERS-COV' named entity 'DEVELOPMENT' named entity 'ELISAS' named entity 'INDIRECT' named entity 'ELISAS' named entity 'CURRENT' named entity 'CAUSED' named entity 'REDUCTION' named entity 'LARGE' named entity 'RESOURCE' named entity 'SENSITIVITY AND SPECIFICITY' named entity 'CASES' named entity 'VALUES' named entity 'OUR' named entity 'BETTER' named entity 'NUCLEOCAPSID PROTEIN' named entity 'LIVE' named entity 'VALIDATION' named entity 'DIFFERENT' named entity 'CONTRAST' named entity 'COUNTRIES' named entity 'COMPARED' named entity 'ACIDS' named entity 'RELIABLE' named entity 'SEROLOGICAL' named entity 'PROTEIN ' named entity '28S' named entity 'MERS-COV' named entity 'NEUTRALIZATION' named entity 'TRAINED' named entity '725' named entity 'REPRESENT' named entity 'MAINTAINED' named entity 'HANDLING' named entity 'CONFIRMED' named entity 'TESTING' named entity 'NUMBER OF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software